Mirum Pharmaceuticals Inc (STU:08D)
€ 38.8 0.6 (1.57%) Market Cap: 1.92 Bil Enterprise Value: 1.95 Bil PE Ratio: 0 PB Ratio: 8.72 GF Score: 52/100

Q2 2023 Mirum Pharmaceuticals Inc Earnings Call Transcript

Aug 03, 2023 / 08:30PM GMT
Release Date Price: €22.6
Operator

Good afternoon. And thank you all for joining. I would like to welcome you all to the Mirum Pharmaceuticals Report Second Quarter 2023 Financial Results and provide business update. My name is Brika, and I'll be your moderator for today's call. (Operator Instructions)

I would now like to turn the call over to Andrew McKibben, VP, Investor Relations and Finance. So Andrew, please go ahead.

Andrew McKibben
Mirum Pharmaceuticals, Inc. - VP of IR and Finance

Thanks, Brika, and good afternoon, everyone. I'd like to welcome you to Mirum Pharmaceuticals Second Quarter 2023 Conference Call. I'm joined today by our President and CEO, Chris Peetz; our Chief Operating Officer, Peter Radovich, and our Head of Research and Development, Pam Vig. Earlier today, Mirum issued a news release announcing the company's results for the second quarter of 2023. Copies of this news release and SEC filings can be found in the Investors section of our website. Full details and updates from the quarter can be found in our news release.

Before we begin, I'd like to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot